Abstract:INTRODUCTION:Prostate cancer (PCa) is the most commonly diagnosed cancer and the third leading cause of cancer-related death in males in the United States. Despite the initial efficacy of androgen deprivation therapy in prostate cancer (PCa) patients, most patients progress to castration-resistant prostate cancer. However, the mechanisms underlying the androgen-independent progression of PCa remain largely unknown.METHODS:In this study, we established a PCa cell line (LNCaP-AI) by maintaining LNCaP cells under androgen-depleted conditions. To explore the cellular and molecular mechanisms of androgen-independent growth of PCa, we analyzed the gene expression patterns in androgen-independent prostate cancer (AIPC) compared with that in androgen-dependent prostate cancer (ADPC). KEGG pathway analysis revealed that Wnt signaling pathways were activated after androgen deprivation therapy (ADT). In vitro experiments showed that the inhibition of Wnt pathway reduced AIPC cell growth by inhibiting cell cycle progression and promoting apoptosis. Furthermore, WNT5A, LEF1 were identified as direct targets of AR by chromatin immunoprecipitation (ChIP) assay and public ChIP-seq datasets analysis.RESULTS:In the present study, we found a regulatory mechanism through which crosstalk between androgen receptor (AR) and Wnt signals promoted androgen-independent conversion of PCa. The Wnt pathway was inhibited by androgen in androgen-dependent prostate cancer cells, but this blocking effect was not elicited in androgen-independent prostate cancer (AIPC) cells. Moreover, Wnt pathway genes WNT5A and LEF1 were directly downregulated by AR. In vitro experiments showed that inhibition of the Wnt pathways repressed AIPC cell growth by inhibiting cell cycle progression and promoting apoptosis. We found that WNT5A and LEF1 were downregulated in low-grade PCa but upregulated in metastatic PCa.CONCLUSION:In summary, we revealed that crosstalk between AR and Wnt signaling pathways promotes androgen-independent growth of PCa, which may provide novel therapeutic opportunities for castration-resistant prostate cancer.

A Human- And Male-Specific Protocadherin That Acts Through The Wnt Signaling Pathway To Induce Neuroendocrine Transdifferentiation Of Prostate Cancer Cells

Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells

Human Homolog of Drosophila Hairy and Enhancer of Split 1, Hes1, Negatively Regulates Δ-Catenin (CTNND2) Expression in Cooperation with E2F1 in Prostate Cancer

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles

USP54 is a potential therapeutic target in castration-resistant prostate cancer

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Erratum: Complex Regulation of Human Androgen Receptor Expression by Wnt Signaling in Prostate Cancer Cells

PC-1/PrLZ Contributes to Malignant Progression in Prostate Cancer.

CWR22: Androgen-Dependent Xenograft Model Derived from a Primary Human Prostatic Carcinoma.

Expression Profiling of the Mouse Prostate after Castration and Hormone Replacement: Implication of H-cadherin in Prostate Tumorigenesis.

Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer

Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis

Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer

LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production

Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor

Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth

PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer

Pir-001773 and Pir-017184 Promote Prostate Cancer Progression by Interacting with PCDH9.

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation